Protective effects of mastic oil from pistacia lentiscus variation chia against experimental growth of lewis lung carcinoma

Nutrition and Cancer

Volumn 61, Issue 5, 2009, Pages 640-648

  Magkouta, Sophia ^a   Stathopoulos, Georgios T ^a   Psallidas, Ioannis ^a   Papapetropoulos, Andreas ^b   Kolisis, Fragiskos N ^c   Roussos, Charis ^a   Loutrari, Heleni ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; ESSENTIAL OIL; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MASTIC OIL; PERILLYL ALCOHOL; PINENE; RAS PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VEGETABLE OIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER PREVENTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PISTACIA LENTISCUS; PROTEIN EXPRESSION; REPORTER GENE; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; INFLAMMATION MEDIATORS; MALE; MEDICINE, TRADITIONAL; MICE; MICE, INBRED C57BL; MONOTERPENES; NEOPLASM TRANSPLANTATION; PHYTOTHERAPY; PISTACIA; PLANT OILS; SIGNAL TRANSDUCTION; TUMOR BURDEN;

MUS; PISTACIA LENTISCUS;

EID: 70449678675     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580902825647     Document Type: Article

References (52)

1. Jemal A,Murray T,Ward E, Samuels A, Tiwari RC, et al.: Cancer statistics, 2005. CA Cancer J Clin 55, 10-30, 2005.
2. Miller AB, Altenburg HP, Bueno-de-Mesquita B, Boshuizen HC, Agudo A, et al.: Fruits and vegetables and lung cancer: findings from the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 108, 269-276, 2004.
3. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3, 768-780, 2003.
4. Greenwald P: Clinical trials in cancer prevention: current results and perspectives for the future. J Nutr 134, 3507S-3512S, 2004.
5. Brenner DE and Gescher AJ: Cancer chemoprevention: lessons learned and future directions. Br J Cancer 93, 735-739, 2005.
6. World Cancer Research Fund/American Institute for Cancer Research: Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. Washington, DC: AICR, 2007.
7. Khan N, Afaq F, and Mukhtar H: Apoptosis by dietary factors: the suicide solution for delaying cancer growth. Carcinogenesis 28, 233-239, 2007.
8. Singh RP and Agarwal R: Tumor angiogenesis: A potential target in cancer control by phytochemicals. Curr Cancer Drug Targets 3, 205-217, 2003.
9. Murakami A and Ohigashi H: Targeting NOX, INOS, and COX-2 in inflammatory cells: chemoprevention using food phytochemicals. Int J Cancer 121, 2357-2363, 2007.
10. D'Incalci M, Brunelli D, Marangon E, Simone M, Tavecchio M, et al.: Modulation of gene transcription by natural products-a viable anticancer strategy. Curr Pharm Des 13, 2744-2750, 2007.
11. Crowell PL: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129, 775S-778S, 1999.
12. MoHand ElsonCE: Studies of the isoprenoid-mediated inhibition ofmevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med (Maywood) 229, 567-585, 2004.
13. Belanger JT: Perillyl alcohol: Applications in oncology. Altern Med Rev 3, 448-457, 1998.
14. Ripple GH, Gould MN, Arzoomanian RZ, Alberti D, Feierabend C, et al.: Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Clin Cancer Res 6, 390-396, 2000.
15. Liu G, Oettel K, Bailey H, Ummersen LV, Tutsch K, et al.: Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer. Invest New Drugs, 21, 367-372, 2003.
16. Loutrari H, Hatziapostolou M, Skouridou V, Papadimitriou E, Roussos C, et al.: Perillyl alcohol is an angiogenesis inhibitor. J Pharmacol Exp Ther 311, 568-575, 2004.
17. Liu RH: Potential synergy of phytochemicals in cancer prevention: mechanism of action. J Nutr 134, 3479S-3485S, 2004.
18. de Kok TM, Van Breda SG, and Manson MM: Mechanisms of combined action of different chemopreventive dietary compounds: A review. Eur J Nutr 47(2 Suppl), 51-59, 2008.
19. Papageorgiou V, Sagredos A, and Moser R: GLC-MS computer analysis of the essential oil of mastic gum. Chim Chronica, New Ser 10, 119-124, 1981.
20. Magiatis P, Melliou E, Skaltsounis AL, Chinou IB, and Mitaku S: Chemical composition and antimicrobial activity of the essential oils of Pistacia lentiscus var. chia. Planta Med 65, 749-752, 1999.
21. Koutsoudaki C, Krsek M, and Rodger A: Chemical composition and antibacterial activity of the essential oil and the gum of Pistacia lentiscus Var. chia. J Agric Food Chem 53, 7681-7685, 2005.
22. Huwez FU, Thirlwell D, Cockayne A, and Ala'Aldeen DA: Mastic gum kills Helicobacter pylori. N Engl J Med 339, 1946, 1998.
23. Paraschos S, Magiatis P, Mitakou S, Petraki K, Kalliaropoulos A, et al.: In vitro and in vivo activities of Chios mastic gum extracts and constituents against Helicobacter pylori. Antimicrob Agents Chemother 51, 551-559, 2007.
24. Dedoussis GV, Kaliora AC, Psarras S, Chiou A, Mylona A, et al.: Antiatherogenic effect of Pistacia lentiscus via GSH restoration and downregulation of CD36 mRNA expression. Atherosclerosis 174, 293-303, 2004.
25. Kaliora AC, Stathopoulou MG, Triantafillidis JK, Dedoussis GV, and Andrikopoulos NK: Alterations in the function of circulating mononuclear cells derived from patients with Crohn's disease treated with mastic. World J Gastroenterol 13, 6031-6036, 2007.
26. Kang JS,Wanibuchi H, Salim EI,Kinoshita A, and Fukushima S: Evaluation of the toxicity of mastic gum with 13 weeks dietary administration to F344 rats. Food Chem Toxicol 45, 494-501, 2007.
27. Loutrari H, Magkouta S, Pyriochou A, Koika V, Kolisis FN, et al.: Mastic oil from Pistacia lentiscus var. chia inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis. Nutr Cancer 55, 86-93, 2006.
28. He ML, Yuan HQ, Jiang AL, Gong AY, Chen WW, et al.: Gum mastic inhibits the expression and function of the androgen receptor in prostate cancer cells. Cancer 106, 2547-2555, 2006.
29. He ML, Li A, Xu CS, Wang SL, Zhang MJ, et al.: Mechanisms of antiprostate cancer by gum mastic: NF-kappaB signal as target. Acta Pharmacol Sin 28, 446-452, 2007.
30. Balan KV, Prince J, Han Z, Dimas K, Cladaras M, et al.: Antiproliferative activity and induction of apoptosis in human colon cancer cells treated in vitro with constituents of a product derived from Pistacia lentiscus L. var. chia. Phytomedicine 14, 263-272, 2007.
31. Stathopoulos GT, Zhu Z, Everhart MB, Kalomenidis I, Lawson et al.: Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion. Am J Respir Cell Mol Biol 34, 142-150, 2006.
32. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65, 55-63, 1983.
33. Weihua Z, Saji S, Makinen S, Cheng G, Jensen EV, et al.: Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc Natl Acad Sci USA 97, 5936-5941, 2000.
34. Ogawa Y, Chung YS, Nakata B, Takatsuka S, Maeda K, et al.: Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. Br J Cancer 71, 1297-1301, 1995.
35. Gavrieli Y, Sherman Y, and Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119, 493-501, 1992.
36. Stathopoulos GT, Moschos C, Loutrari H, Kollintza A, Psallidas I, et al.: Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 178, 50-59, 2008.
37. Yuri T, Danbara N, Tsujita-Kyutoku M, Kiyozuka Y, Senzaki H, et al.: A. perillyl alcohol inhibits human breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 84, 251-260, 2004.
38. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69(3 Suppl), 4-10, 2005.
39. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 4, 540-550, 2004.
40. Jaffe AB and Hall A: Rho GTPases in transformation and metastasis. Adv Cancer Res 84, 57-80, 2002.
41. Downward J: Targeting RAS signaling pathways in cancer therapy. Nat Rev Cancer 3, 11-22, 2003.
42. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441, 431-436, 2006.
43. Folkman J: Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18, 2002.
44. MantoVani A, Allavena P, Sica A, and Balkwill F: Cancer-related inflammation. Nature 454, 436-444, 2008.
45. Hong KH, Ryu J, and Han KH: Monocyte chemoattractant protein-1- induced angiogenesis is mediated by vascular endothelial growth factor-A. Blood 105, 1405-1407, 2005.
46. Cherqui S, Kingdon KM, Thorpe C, Kurian SM, and Salomon DR: Lentiviral gene delivery of vMIP-II to transplanted endothelial cells and endothelial progenitors is proangiogenic in vivo. Mol Ther 15, 1264-1272, 2007.
47. Fritz G, Just I, and Kaina B: Rho GTPases are over-expressed in human tumors. Int J Cancer 81, 682-687, 1999.
48. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, et al.: The role of RAS oncogene in survival of patients with lung cancer: A systematic review of the literature with meta-analysis. Br J Cancer 92, 131-139, 2005.
49. Finco TS, Westwick JK, Norris JL, Beg AA, Der CJ, et al.: Oncogenic Ha- Ras-induced signaling activates NF-kappaB transcriptional activity, which is required for cellular transformation. J Biol Chem 272, 24113-24116, 1997.
50. Cammarano MS and Minden A: Dbl and the Rho GTPases activate NF kappa B by I kappa B kinase (IKK)-dependent and IKK-independent pathways. J Biol Chem 276, 25876-25882, 2001.
51. Berchtold CM, Chen KS, Miyamoto S, and Gould MN: Perillyl alcohol inhibits a calcium-dependent constitutive nuclear factor-kappaB pathway. Cancer Res 65, 8558-8566, 2005.
52. Milner JA: Nutrition and cancer: essential elements for a roadmap. Cancer Lett 269, 189-198, 2008.